<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; Cancer Research</title>
	<atom:link href="http://www.bioscreening.net/category/news/cancer-research/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Mon, 21 May 2012 14:33:52 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Scientists Describe New Genetic Subtypes of Prostate Cancer</title>
		<link>http://www.bioscreening.net/2012/05/21/scientists-describe-new-genetic-subtypes-of-prostate-cancer/</link>
		<comments>http://www.bioscreening.net/2012/05/21/scientists-describe-new-genetic-subtypes-of-prostate-cancer/#comments</comments>
		<pubDate>Mon, 21 May 2012 14:33:52 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1575</guid>
		<description><![CDATA[Two independent exome sequencing studies have identified new genetic subtypes of prostate cancer. Presenting its findings in Nature, a University of Michigan Medical School-led team identified CHD1 mutations in 8% of heavily pretreated lethal metastatic castration-resistant prostate cancers (CRPCs). Notably, CHD1 mutations were almost always found in tumors that didn’t display ETS gene family fusions. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2012/05/21/scientists-describe-new-genetic-subtypes-of-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ventana Licenses Gen-Probe IP for Measuring ERG Protein in Prostate Cancer</title>
		<link>http://www.bioscreening.net/2012/05/21/ventana-licenses-gen-probe-ip-for-measuring-erg-protein-in-prostate-cancer/</link>
		<comments>http://www.bioscreening.net/2012/05/21/ventana-licenses-gen-probe-ip-for-measuring-erg-protein-in-prostate-cancer/#comments</comments>
		<pubDate>Mon, 21 May 2012 14:06:12 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1568</guid>
		<description><![CDATA[Roche’s Ventana Medical Systems co-exclusively sublicensed IP from Gen-Probe granting the firm in vitro diagnostic rights relating to the immunohistochemical measurement of ERG protein expression in prostate tissue. Ventana says the licensed IP complements its existing co-exclusive sublicense to IP covering in situ hybridization measurements of ETS gene rearrangements (including ERG gene rearrangements) in tissue. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2012/05/21/ventana-licenses-gen-probe-ip-for-measuring-erg-protein-in-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioDelivery Earns $2.5M from Meda on Pricing Approval of Breakyl in First EU Country</title>
		<link>http://www.bioscreening.net/2012/05/21/biodelivery-earns-2-5m-from-meda-on-pricing-approval-of-breakyl-in-first-eu-country/</link>
		<comments>http://www.bioscreening.net/2012/05/21/biodelivery-earns-2-5m-from-meda-on-pricing-approval-of-breakyl-in-first-eu-country/#comments</comments>
		<pubDate>Mon, 21 May 2012 13:56:29 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1565</guid>
		<description><![CDATA[BioDelivery Sciences received a $2.5 million prelaunch milestone payment from Meda, triggered by the first national regulatory clearance and pricing approval for Breakyl/Onsolis (fentanyl buccal soluble film) in the EU. Breakyl is indicated for the management of breakthrough pain in opioid-tolerant adult cancer patients. BioDelivery will receive another, final $2.5 million EU-related milestone when the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2012/05/21/biodelivery-earns-2-5m-from-meda-on-pricing-approval-of-breakyl-in-first-eu-country/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Google Search Engine Forms Basis of Algorithm to Identify Prognostic Cancer Biomarkers</title>
		<link>http://www.bioscreening.net/2012/05/18/google-search-engine-forms-basis-of-algorithm-to-identify-prognostic-cancer-biomarkers/</link>
		<comments>http://www.bioscreening.net/2012/05/18/google-search-engine-forms-basis-of-algorithm-to-identify-prognostic-cancer-biomarkers/#comments</comments>
		<pubDate>Fri, 18 May 2012 15:36:30 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1559</guid>
		<description><![CDATA[Scientists have adapted the algorithm used by Google’s web search engine to develop a computational program that can identify panels of biomarkers for cancer prognosis. Google’s PageRank algorithm takes into account the network of hyperlinks between web documents as well as the search terms themselves to determine which pages are most relevant to a particular [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2012/05/18/google-search-engine-forms-basis-of-algorithm-to-identify-prognostic-cancer-biomarkers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ruga Licenses Selexagen’s RAF Kinase Program for Targeted Cancer Therapy</title>
		<link>http://www.bioscreening.net/2012/05/18/ruga-licenses-selexagens-raf-kinase-program-for-targeted-cancer-therapy/</link>
		<comments>http://www.bioscreening.net/2012/05/18/ruga-licenses-selexagens-raf-kinase-program-for-targeted-cancer-therapy/#comments</comments>
		<pubDate>Fri, 18 May 2012 15:15:06 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[South America]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1555</guid>
		<description><![CDATA[Targeted cancer drug developer Ruga negotiated rights to Selexagen Therapeutics’ RAF kinase program. The firm claims the acquired technology addresses the drawbacks to BRAF inhibition as an approach to cancer therapy. Data has demonstrated that BRAF inhibition can actually induce adaptation in RAS-activated cells and promote the development of secondary skin lesions and RAS-mutated tumor [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2012/05/18/ruga-licenses-selexagens-raf-kinase-program-for-targeted-cancer-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Four anti-cancer compounds identified</title>
		<link>http://www.bioscreening.net/2011/12/02/four-anti-cancer-compounds-identified/</link>
		<comments>http://www.bioscreening.net/2011/12/02/four-anti-cancer-compounds-identified/#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:38:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1363</guid>
		<description><![CDATA[Sydney: Four new anti-cancer compounds have shown promise in inhibiting the growth of tumours, according to a new approach. Jason Smith, doing his M.Phil. in biomolecular sciences from Macquarie University, combined existing knowledge of an enzyme with computational chemistry approach to identify novel (cancer) inhibitors. The enzyme (indoleamine 2,3-dioxygenase) has generated excitement amongst researchers due [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/12/02/four-anti-cancer-compounds-identified/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nigeria: FG and Cost of Cancer Screening</title>
		<link>http://www.bioscreening.net/2011/11/28/nigeria-fg-and-cost-of-cancer-screening/</link>
		<comments>http://www.bioscreening.net/2011/11/28/nigeria-fg-and-cost-of-cancer-screening/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 18:03:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Africa]]></category>
		<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Compound Screening]]></category>
		<category><![CDATA[Genetics & Pharmacogenetics]]></category>
		<category><![CDATA[HT Screening]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1352</guid>
		<description><![CDATA[THE Federal Government&#8217;s recent directive to its hospitals to reduce the cost of cancer screening, though very commendable, is long overdue, considering that late diagnosis of the disease has resulted in the high rate of cancer related deaths in the country. Cancer is one of the leading causes of deaths in the world, especially in [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/28/nigeria-fg-and-cost-of-cancer-screening/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Coffee Drinking Linked To Lower Risk Of Common Skin Cancer</title>
		<link>http://www.bioscreening.net/2011/10/25/coffee-drinking-linked-to-lower-risk-of-common-skin-cancer/</link>
		<comments>http://www.bioscreening.net/2011/10/25/coffee-drinking-linked-to-lower-risk-of-common-skin-cancer/#comments</comments>
		<pubDate>Tue, 25 Oct 2011 15:19:27 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1307</guid>
		<description><![CDATA[New research presented at a conference in the US on Monday finds that drinking coffee is linked to a lower risk of a common form of skin cancer known as basal cell carcinoma (BCC). Results of a prospective study that followed over 25,000 cases of skin cancer suggest coffee may be an important dietary option [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/10/25/coffee-drinking-linked-to-lower-risk-of-common-skin-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>7TH DUESSELDORF SYMPOSIUM ON IMMUNOTOXICOLOGY Biology of the Arylhydrocarbon Receptor</title>
		<link>http://www.bioscreening.net/2011/09/13/7th-duesseldorf-symposium-on-immunotoxicology-biology-of-the-arylhydrocarbon-receptor/</link>
		<comments>http://www.bioscreening.net/2011/09/13/7th-duesseldorf-symposium-on-immunotoxicology-biology-of-the-arylhydrocarbon-receptor/#comments</comments>
		<pubDate>Tue, 13 Sep 2011 16:27:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1285</guid>
		<description><![CDATA[Heinrich Heine University Duesseldorf September 21 &#8211; 24, 2011 AhR research has taken great momentum recently, with a number of seminal discoveries, especially regarding its role in physiological events. This has opened new arenas, attracted new groups into the field, and led to a steep interest in the potential of AhR as a therapeutic target [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/09/13/7th-duesseldorf-symposium-on-immunotoxicology-biology-of-the-arylhydrocarbon-receptor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Canadian-made virus shows promise as cancer treatment</title>
		<link>http://www.bioscreening.net/2011/08/31/canadian-made-virus-shows-promise-as-cancer-treatment/</link>
		<comments>http://www.bioscreening.net/2011/08/31/canadian-made-virus-shows-promise-as-cancer-treatment/#comments</comments>
		<pubDate>Wed, 31 Aug 2011 20:32:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1272</guid>
		<description><![CDATA[An Ottawa-based research team has developed a virus that is showing promise as a new way of attacking and shrinking cancer tumours while leaving healthy tissue alone. It&#8217;s early days in the still-experimental field of therapeutic cancer viruses, called oncolytic viruses. But this new study from researchers from the Ottawa Hospital Research Institute (OHRI) and the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/31/canadian-made-virus-shows-promise-as-cancer-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genetic Link Predisposes to Mesothelioma</title>
		<link>http://www.bioscreening.net/2011/08/29/genetic-link-predisposes-to-mesothelioma/</link>
		<comments>http://www.bioscreening.net/2011/08/29/genetic-link-predisposes-to-mesothelioma/#comments</comments>
		<pubDate>Mon, 29 Aug 2011 15:34:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[Genetics & Pharmacogenetics]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1269</guid>
		<description><![CDATA[An investigation led by scientists at the University of Hawaii Cancer Center, Honolulu, and Fox Chase Cancer Center, Philadelphia has identified germline mutations in the BAP1 gene that predispose individuals to malignant mesothelioma. The research, published online yesterday in Nature Genetics, describes two U.S. families with a high incidence of mesothelioma, as well as other [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/29/genetic-link-predisposes-to-mesothelioma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Combining Gene and Cell Therapy Is Arming Researchers with More Options for Cancer</title>
		<link>http://www.bioscreening.net/2011/08/22/combining-gene-and-cell-therapy-is-arming-researchers-with-more-options-for-cancer/</link>
		<comments>http://www.bioscreening.net/2011/08/22/combining-gene-and-cell-therapy-is-arming-researchers-with-more-options-for-cancer/#comments</comments>
		<pubDate>Mon, 22 Aug 2011 14:46:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1263</guid>
		<description><![CDATA[A few years ago most pharma and biotech companies ran away from autologous therapies, especially complex cell-based treatments. Following Dendreon’s introduction of its autologous dendritic cell therapy to treat prostate cancer, however, researchers are venturing into one-off treatments for difficult to treat diseases. In a huge scientific boost to the entire field of cell-based adoptive [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/22/combining-gene-and-cell-therapy-is-arming-researchers-with-more-options-for-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Adding caffeine to sunscreen could guard against skin cancer</title>
		<link>http://www.bioscreening.net/2011/08/18/adding-caffeine-to-sunscreen-could-guard-against-skin-cancer/</link>
		<comments>http://www.bioscreening.net/2011/08/18/adding-caffeine-to-sunscreen-could-guard-against-skin-cancer/#comments</comments>
		<pubDate>Thu, 18 Aug 2011 16:18:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[Genetics & Pharmacogenetics]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Research Projects]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1257</guid>
		<description><![CDATA[Scientists have worked out how caffeine might protect against certain skin cancers – a finding that could lead to better sunscreens. The research, conducted in mice, suggests that caffeine changes the activity of a gene involved in the destruction of cells that have DNA damage and are therefore more likely to become cancerous. The scientists [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/18/adding-caffeine-to-sunscreen-could-guard-against-skin-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Blood Antibody May Signal Start of Ovarian Cancer</title>
		<link>http://www.bioscreening.net/2011/08/17/blood-antibody-may-signal-start-of-ovarian-cancer/</link>
		<comments>http://www.bioscreening.net/2011/08/17/blood-antibody-may-signal-start-of-ovarian-cancer/#comments</comments>
		<pubDate>Wed, 17 Aug 2011 18:49:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1253</guid>
		<description><![CDATA[WEDNESDAY, Aug. 17 (HealthDay News) &#8212; Researchers have found an antibody that might someday be useful in identifying women who have a higher risk of ovarian cancer, or possibly diagnosing early ovarian cancer. This particular antibody, which was detected in blood, develops as an immune system response to a protein called mesothelin. This protein is [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/17/blood-antibody-may-signal-start-of-ovarian-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Five Genes May Be Tied to Lethal Prostate Cancer</title>
		<link>http://www.bioscreening.net/2011/08/16/five-genes-may-be-tied-to-lethal-prostate-cancer/</link>
		<comments>http://www.bioscreening.net/2011/08/16/five-genes-may-be-tied-to-lethal-prostate-cancer/#comments</comments>
		<pubDate>Tue, 16 Aug 2011 18:42:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[Genetics & Pharmacogenetics]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1250</guid>
		<description><![CDATA[TUESDAY, Aug. 16 (HealthDay News) &#8212; In what may be a diagnostic advance, U.S. and Swedish researchers have linked five inherited genetic mutations to the development of a particularly aggressive and deadly form of prostate cancer. The findings could someday lead to development of an easy-to-administer blood test to screen for such mutations to help [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/16/five-genes-may-be-tied-to-lethal-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Urine Test May Help Detect, Stratify Prostate Cancer</title>
		<link>http://www.bioscreening.net/2011/08/04/urine-test-may-help-detect-stratify-prostate-cancer/</link>
		<comments>http://www.bioscreening.net/2011/08/04/urine-test-may-help-detect-stratify-prostate-cancer/#comments</comments>
		<pubDate>Thu, 04 Aug 2011 15:07:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1235</guid>
		<description><![CDATA[In men with elevated prostate specific antigen (PSA), an investigational urine test can detect and stratify prostate cancer, researchers reported. The test is based on the detection of a gene fusion that is specific to prostate cancer, combined with another marker, according to Arul Chinnaiyan, MD, PhD, of the University of Michigan Medical School in [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/04/urine-test-may-help-detect-stratify-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Scientists Claim Leukemia Stem Cell Signature Independently Predicts Poor Survival in AML</title>
		<link>http://www.bioscreening.net/2011/08/02/scientists-claim-leukemia-stem-cell-signature-independently-predicts-poor-survival-in-aml/</link>
		<comments>http://www.bioscreening.net/2011/08/02/scientists-claim-leukemia-stem-cell-signature-independently-predicts-poor-survival-in-aml/#comments</comments>
		<pubDate>Tue, 02 Aug 2011 15:27:55 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1276</guid>
		<description><![CDATA[Research on samples from human acute myeloid leukemia (AML) patients has suggested that the a leukemia stem cell (LSC) gene expression profile can accurately be used to predict patient survival, even among AML patients with cytogenetically normal disease. An international team led by researchers at Ontario’s University Health Network and the University of Toronto’s Department [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/02/scientists-claim-leukemia-stem-cell-signature-independently-predicts-poor-survival-in-aml/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Women who eat lots of fiber have less breast cancer</title>
		<link>http://www.bioscreening.net/2011/07/29/women-who-eat-lots-of-fiber-have-less-breast-cancer/</link>
		<comments>http://www.bioscreening.net/2011/07/29/women-who-eat-lots-of-fiber-have-less-breast-cancer/#comments</comments>
		<pubDate>Fri, 29 Jul 2011 15:35:55 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1224</guid>
		<description><![CDATA[(Reuters Health) &#8211; A fresh look at the medical evidence shows women who eat more fiber are less likely to get breast cancer. Chinese researchers found those who ate the most of the healthy plant components were 11 percent less likely to develop breast cancer than women who ate the least. Their findings don&#8217;t prove [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/07/29/women-who-eat-lots-of-fiber-have-less-breast-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genentech to Appeal to F.D.A. for Breast Cancer Drug</title>
		<link>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/</link>
		<comments>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/#comments</comments>
		<pubDate>Mon, 27 Jun 2011 15:10:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1182</guid>
		<description><![CDATA[Genentech this week will step up its efforts to keep the drug Avastin available as a treatment for breast cancer, urging the Food and Drug Administration to give it one more chance to prove the medicine works. At a hearing on Tuesday and Wednesday in suburban Washington, Genentech will ask the F.D.A. to reconsider its [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UPDATE 1-Pfizer stop-smoking pill raises heart risk-FDA</title>
		<link>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/</link>
		<comments>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/#comments</comments>
		<pubDate>Fri, 17 Jun 2011 15:13:48 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1163</guid>
		<description><![CDATA[WASHINGTON, June 16 (Reuters) &#8211; Pfizer Inc&#8217;s (PFE.N) stop-smoking drug Chantix can lead to a small increase in cardiovascular problems such as heart attacks for patients who already have cardiovascular disease, U.S. drug regulators said on Thursday. The Food and Drug Administration is changing the label for Chantix after reviewing the results of a clinical [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/17/update-1-pfizer-stop-smoking-pill-raises-heart-risk-fda/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

